Insider Buying: Profound Medical (TSE:PRN) Insider Buys C$35,447.20 in Stock

Profound Medical Corp. (TSE:PRN) insider Thomas Michael Tamberrino purchased 3,755 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were acquired at an average cost of C$9.44 per share, with a total value of C$35,447.20. Following the completion of the acquisition, the insider directly owned 53,573 shares in the company, valued at approximately C$505,729.12. This represents a 7.54% increase in their ownership of the stock.

Profound Medical Price Performance

Profound Medical stock opened at C$9.75 on Thursday. The company has a debt-to-equity ratio of 14.82, a quick ratio of 14.98 and a current ratio of 6.46. The firm has a market cap of C$356.20 million, a P/E ratio of -9.85 and a beta of 1.30. The business’s fifty day moving average is C$9.88 and its two-hundred day moving average is C$9.35. Profound Medical Corp. has a 52 week low of C$5.23 and a 52 week high of C$12.40.

Profound Medical (TSE:PRN) last announced its earnings results on Thursday, August 6th. The company reported C($0.37) EPS for the quarter. Profound Medical had a negative return on equity of 62.45% and a negative net margin of 170.92%.The business had revenue of C$3.53 million for the quarter. Equities research analysts forecast that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Raymond James Financial raised shares of Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, July 27th. Eight analysts have rated the stock with a Buy rating, sixteen have assigned a Moderate Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of C$9.75.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.